NICE recommends Sobi’s Kineret for first-line use in Still’s disease
Biologic therapy approved to treat systemic juvenile idiopathic arthritis and adult-onset Still’s disease
Read More
Tag: Still’s disease
Novartis’ Ilaris first drug approved for Still’s disease
Ilaris works by blocking the effects of IL-1 and suppressing inflammation in patients with this autoinflammatory disorder
Read More
Four new therapies to be funded by NHS Scotland
The Scottish Medicines Consortium has endorsed NHS funding for four therapies, offering new treatment options for acute myeloid leukaemia, Still’s disease, adrenal insufficiency and psoriatic arthritis.
Read More
EU regulators expand reach of Sobi’s Kineret
European regulators have expanded the scope of Sobi’s Kineret to include the treatment of Still’s disease, a rare, systemic, multi-organ, auto-inflammatory disorder that affects around 25,000 children and adults in the EU.
Read More
- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
